Kanopas 20 mg Tablet is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist indicated for adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). It is clinically proven to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure. Kanopas 20 mg plays an important role in slowing kidney disease progression while offering significant cardiovascular protection in high-risk patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Kanopas 20 mg is indicated to reduce the risk of:

• Sustained eGFR decline

• End-stage kidney disease

• Cardiovascular death

• Non-fatal myocardial infarction

• Hospitalization for heart failure

in adult patients with CKD associated with type 2 diabetes.

Dosage and Administration

Before initiating Kanopas 20 mg, serum potassium levels and eGFR must be measured.

• Do not initiate treatment if serum potassium is >5.0 mEq/L

• Dosage is based on eGFR:

  • eGFR ≥60 mL/min/1.73 m²: 20 mg once daily

  • eGFR ≥25 to <60 mL/min/1.73 m²: 10 mg once daily

  • eGFR <25 mL/min/1.73 m²: Not recommended

Tablets should be taken orally once daily. For patients unable to swallow whole tablets, Kanopas may be crushed and mixed with water or soft foods such as applesauce and administered immediately.

Drug Interactions

• Strong CYP3A4 inhibitors: Contraindicated due to increased drug exposure and risk of adverse reactions. Avoid grapefruit or grapefruit juice.

• Moderate or weak CYP3A4 inhibitors: May increase exposure. Monitor serum potassium during initiation or dose adjustments.

• Strong or moderate CYP3A4 inducers: May reduce efficacy. Concomitant use should be avoided.

Contraindications

Kanopas 20 mg is contraindicated in patients:

• Receiving concomitant treatment with strong CYP3A4 inhibitors

• With adrenal insufficiency

Side Effects

The most clinically significant adverse reaction associated with Kanopas 20 mg is:

• Hyperkalemia

Precautions and Warnings

Kanopas 20 mg can cause hyperkalemia, with risk increasing in patients with reduced kidney function or higher baseline potassium levels. Serum potassium and eGFR should be assessed prior to initiation and monitored periodically during treatment. More frequent monitoring may be required in patients taking other medications that increase serum potassium or impair potassium excretion.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Kanopas 20 mg is a nonsteroidal, selective antagonist of the mineralocorticoid receptor. By blocking MR activation by aldosterone and cortisol, it reduces sodium reabsorption and prevents MR overactivation in kidney, heart, and vascular tissues. This action helps limit inflammation and fibrosis, key contributors to kidney and cardiovascular disease progression. Kanopas demonstrates high selectivity for the MR with no significant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.

Use in Special Populations

• Pregnancy and Lactation: Not recommended due to potential fetal and infant risk. Avoid breastfeeding during treatment and for 1 day after discontinuation.

• Pediatric Use: Safety and efficacy not established in patients under 18 years.

• Geriatric Use: No dose adjustment required.

• Hepatic Impairment: Avoid in severe hepatic impairment. Monitor serum potassium in moderate impairment.

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.